Chest PNF on Pulmonary Function in Parkinson Disease

Not Applicable

• Conditions: Parkinson Disease

• Registration Number: NCT03977740
• Lead Sponsor: Subhasish Chatterjee

Brief Summary

Background: Parkinson disease (PD) is a progressive neurodegenerative disorder and characterized by tremor, rigidity and bradykinesia. Almost 84% of PD patient develops respiratory abnormalities and pointed as the most common cause of death. Airway obstruction, trunk muscle rigidity is the common cause of respiratory abnormalities.

Purpose: The main purpose of the study will evaluate the efficacy of chest PNF on pulmonary function and chest wall mobility in PD.

Methods: 20 participants will be recruited for study purpose and divide into two groups. Group= A will be the control group and participants will receive conventional treatment which includes deep breathing exercise and segmental breathing exercise, incentive spirometry etc for one week. Group= B participants will receive chest PNF exercise along with conventional treatment for a week. Pretreatment and post-treatment data will be recorded by the help of PFT (FVC, FEV1 \& FEV1/FVC) and chest wall expansion at axillary and xiphisternal level for data analysis. Data analysis will be done by paired t-test for within group and independent t-test will be used for the between-group variable. The level of significance will be set at 0.05.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Study First Submitted: 2019-05-27
• Status Verified: 2019-06
• Study First Submitted QC: 2019-06-05
• Last Update Submitted: 2019-06-05
• Study First Posted: 2019-06-06
• Last Update Posted: 2019-06-06
• Primary Completion: 2019-06-10
• Study Completion: 2019-06-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Grade 3 to grade 5 Parkinson patients according to Hoehn Yahar scale
2. MMSE score >23.
3. Age 50-70 yrs.
4. Both Male and Female.

Exclusion Criteria

1. Previous history of cardiac and pulmonary surgery.
2. History of flail chest.
3. Individual affected by neurological disorder other than PD.
4. Uncooperative patients.
5. Individual with the psychosomatic disorder.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Primary Outcome Measures

Name	Time	Method
Pulmonary Function Test (PFT)	changes bwtween baseline to 1 week	Pulmonary functions parameters FVC in litre, FEV1 in litre and ratio between FVC/FEV1 will be recorded with PFT

Secondary Outcome Measures

Name	Time	Method
chest wall expansion by inch tape	changes bwtween baseline to 1 week	chest wall expansion will be measured at axillary and xiphisternal level

Trial Locations

Locations (1)

MMIPR; 🇮🇳 Ambāla, Haryana, India